Bleomycin
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-BLEOMYCIN |
|---|---|
| Type | Drug |
| Aliases | BlenoxaneБлеоміцин |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-CHL DIS-TESTICULAR-GCT |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Glycopeptide antitumor antibiotic |
|---|---|
| Mechanism | Generates free radicals causing DNA strand breaks. G2 cell-cycle phase active. Lung tissue lacks bleomycin hydrolase → accumulates → pulmonary toxicity. |
| Typical dosing | ABVD: 10 units/m² IV days 1+15 of 28-day cycle. Cumulative lifetime limit ~400 units (pulmonary toxicity). |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Warnings
- Pulmonary fibrosis (cumulative-dose-dependent, often progressive after exposure)
- Anaphylactoid reactions (test dose advised first)
Notes
Replaced in modern Hodgkin 1L by brentuximab vedotin (A+AVD per ECHELON-1) due to pulmonary toxicity. NEVER combine with brentuximab (additive lung toxicity). Avoid G-CSF on ABVD (increases pulmonary toxicity). Pre-treatment PFT (DLCO) baseline + serial monitoring. Avoid high-flow O2 during anesthesia post-bleomycin (lifetime).
Used By
Regimens
REG-ABVD- ABVD (Adriamycin + Bleomycin + Vinblastine + Dacarbazine), 2-6 cyclesREG-BEP-GCT- BEP (bleomycin + etoposide + cisplatin, germ cell tumor)